H G Derigs
Overview
Explore the profile of H G Derigs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
260
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Kreiter S, Wehler T, Landt O, Huber C, Derigs H, Hess G
Tissue Antigens
. 2001 Jan;
56(5):449-52.
PMID: 11144294
Donor-recipient disparitiy of the minor histocompatibility antigen HA-1 is relevant for the development of graft-versus-host disease after HLA-matched sibling allogeneic bone marrow transplantation in HLA-A*0201-positive individuals. Two different alleles of...
12.
Despres D, Flohr T, Uppenkamp M, Baldus M, Hoffmann M, Huber C, et al.
J Hematother Stem Cell Res
. 2000 Sep;
9(4):557-64.
PMID: 10982256
Several devices for selection of CD34+ peripheral blood stem cells (PBSC) have been used during the last years for reducing tumor cell contamination of the graft. The new CliniMACS system...
13.
Heussel C, Kauczor H, Heussel G, Derigs H, Thelen M
Radiologe
. 2000 Feb;
40(1):88-101.
PMID: 10663171
No abstract available.
14.
Gollner G, Bug G, Rupilius B, Peschel C, Huber C, Derigs H
Cytokine
. 1999 Sep;
11(9):656-63.
PMID: 10479401
Leukaemia inhibitory factor (LIF) plays an important role as a haematopoietically active cytokine. As described earlier in a murine model, interleukin 1 (IL-1) induced LIF mRNA and protein expression. We...
15.
Ostermann H, Derigs H, Heussel G, Kern W, Kiehl M, Kienast J, et al.
Dtsch Med Wochenschr
. 1999 Jul;
124 Suppl 1:S14-7.
PMID: 10410650
No abstract available.
16.
Bug G, Aman J, Huber C, Peschel C, Derigs H
Mediators Inflamm
. 1998 Aug;
7(3):195-9.
PMID: 9705607
The stimulation of granulocyte macrophage-colony stimulating factor (GM-CSF) by interleukin-1 (IL-1) has been shown to be counteracted in different mesenchymal cell systems by cyclic adenosine monophosphate (cAMP) agonists. The aim...
17.
Bokemeyer C, Harstrick A, Beyer J, Metzner B, Ruther U, Hartmann J, et al.
Semin Oncol
. 1998 May;
25(2 Suppl 4):24-32; discussion 45-8.
PMID: 9578059
With the use of a cisplatin-based chemotherapy, metastatic testicular cancer has become a model for a highly curable malignant disease. Current data show that 70% to 80% of patients with...
18.
Kolbe K, Peschel C, Rupilius B, Despres D, Burger K, Sklenar I, et al.
Bone Marrow Transplant
. 1998 Feb;
20(12):1027-32.
PMID: 9466274
Extensive pretreatment has been identified as a significant risk factor for failure of sufficient PBSC mobilization. From published data and our own experience we defined pretreatment variables which render patients...
19.
Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation
Kolbe K, Domkin D, Derigs H, Bhakdi S, Huber C, Aulitzky W
Bone Marrow Transplant
. 1997 Jan;
19(2):143-7.
PMID: 9116611
Type, severity and incidence of infection during the neutropenic period after peripheral blood stem cell transplantation (PBSCT) for treatment of malignant disease were studied in 66 patients treated at a...
20.
Derigs H, Huber C, Mahlke M, Kolbe K
Geburtshilfe Frauenheilkd
. 1996 Apr;
56(4):190-7.
PMID: 8682284
Current Status and Limits: High-dose chemotherapy with autologous haematopoietic stem cell rescue has become in recent years a widely accepted therapeutic modality for advanced stage breast cancer in North America....